Efficacy and Safety of Elranatamab by Age and Frailty in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Subgroup Analysis From MagnetisMM-3

被引：0

作者：

Raje, Noopur ^{[1
]}

Leleu, Xavier ^{[2
]}

Lesokhin, Alexander ^{[3
]}

Mohty, Mohamad ^{[4
,5
]}

Nooka, Ajay K. ^{[6
]}

Leip, Eric ^{[7
]}

Conte, Umberto ^{[8
]}

Viqueira, Andrea ^{[9
]}

Manier, Salomon ^{[10
]}

机构：

[1] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

[2] CHU Poitiers, Hop Mil, Pole Reg Cancerol, Poitiers, France

[3] Mem Sloan Kettering Canc Ctr, Weill Cornell Med Coll, Div Hematol & Oncol, New York, NY USA

[4] Sorbonne Univ, Hop St Antoine, Paris, France

[5] INSERM, UMRs938, Paris, France

[6] Winship Canc Inst, Atlanta, GA USA

[7] Pfizer Inc, Cambridge, MA USA

[8] Pfizer Inc, New York, NY USA

[9] Pfizer SLU, Madrid, Spain

[10] CHU Lille, Lille, France

来源：

关键词：

MM; B-cell maturation antigen; bispecific; clinical trial;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MM-378

引用

页码：S497 / S497

页数：1